Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Hematology & Oncology
Published in: Journal of Hematology & Oncology 1/2021

Open Access 01-12-2021 | NSCLC | Editor's Note

m6A mRNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP activity by regulating the MALAT1-miR-1914-3p-YAP axis to induce NSCLC drug resistance and metastasis

Authors: Dan Jin, Jiwei Guo, Yan Wu, Jing Du, Lijuan Yang, Xiaohong Wang, Weihua Di, Baoguang Hu, Jiajia An, Lingqun Kong, Lei Pan, Guoming Su

Published in: Journal of Hematology & Oncology | Issue 1/2021

Login to get access

Excerpt

Concerns have been raised about the integrity of the data reported in this article [1]. This is currently being investigated. Further editorial action may be taken as appropriate once the investigation into the concerns is complete and all parties have been given an opportunity to respond in full. …
Literature
1.
Metadata
Title
m6A mRNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP activity by regulating the MALAT1-miR-1914-3p-YAP axis to induce NSCLC drug resistance and metastasis
Authors
Dan Jin
Jiwei Guo
Yan Wu
Jing Du
Lijuan Yang
Xiaohong Wang
Weihua Di
Baoguang Hu
Jiajia An
Lingqun Kong
Lei Pan
Guoming Su
Publication date
01-12-2021
Publisher
BioMed Central
Keywords
NSCLC
NSCLC
Published in
Journal of Hematology & Oncology / Issue 1/2021
Electronic ISSN: 1756-8722
DOI
https://doi.org/10.1186/s13045-021-01048-8

Other articles of this Issue 1/2021

Journal of Hematology & Oncology 1/2021 Go to the issue

Review

Therapeutic strategies in METex14 skipping mutated non-small cell lung cancer

Letter to the Editor

A novel CD123-targeted therapeutic peptide loaded by micellar delivery system combats refractory acute myeloid leukemia

Review

Therapeutic roles of mesenchymal stem cell-derived extracellular vesicles in cancer

Rapid communication

Oncogenetic landscape and clinical impact of IDH1 and IDH2 mutations in T-ALL

Letter to the Editor

Clonal evolution in liver cancer at single-cell and single-variant resolution

Review

Targeting neddylation E2s: a novel therapeutic strategy in cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits